Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Ahmed

Internal Medicine Dublin, OH Medical Doctor

NPI 1144308537 CMS profile 594924

6850 Perimeter Dr Ste D, Dublin, OH 43016

Open in the dashboard

General payments

$30,122

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Ahmed of Dublin, OH is reported in the CMS Open Payments database as having received $30,122 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,266 7
2024 General $24,429 24
2023 General $243 5
2021 General $39 2
2020 General $104 6
2019 General $41 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Ahmed
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammed Ahmed were reported at $5,266. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammed Ahmed Internal Medicine median Middle half National median
2019 $41 $159 $48–$570 $163
2020 $104 $119 $33–$402 $114
2021 $39 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $243 $149 $45–$519 $160
2024 $24,429 $154 $47–$537 $164
2025 $5,266 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $29,615 28 payments
  2. Retrophin, Inc. $118 2 payments
  3. Boston Scientific Corporation $109 4 payments
  4. UCB, Inc. $83 4 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $71 1 payment
  6. Celgene Corporation $41 2 payments
  7. Janssen Pharmaceuticals, Inc $37 2 payments
  8. Akebia Therapeutics Inc $21 1 payment
  9. Alkermes, Inc. $14 1 payment
  10. Chiesi USA, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,100 22 payments
  2. Travel and Lodging $1,359 2 payments
  3. Food and Beverage $661 21 payments
  4. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. JARDIANCE $28,239 25 payments
  2. Cimzia $83 4 payments
  3. Kerendia $71 1 payment
  4. BodyGuardian $60 1 payment
  5. Revlimid $41 2 payments
  6. SPRAVATO $37 2 payments
  7. ELUVIA $28 2 payments
  8. Vafseo $21 1 payment
  9. GENERAL ANGIOPLASTY $21 1 payment
  10. INVEGA SUSTENNA $18 1 payment
  11. Other $134 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$48,105

Medicare's payments for the services billed

Medicare patients

248

Average age 48

Services billed

545

105 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 58%
Arthritis 34%
Diabetes 25%
COPD 18%
Alzheimer's or dementia 10%
Ischemic heart disease 9%
Chronic kidney disease 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $23,429
$23,429 — —
ARISTADA
  • Alkermes, Inc. $11
$11 — —
LYBALVI
  • Alkermes, Inc. $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record